ArticleCancer immunology, immunotherapy : CII2012
Regulatory T cells increase in breast cancer and in stage IV breast cancer.
Article in Cancer immunology, immunotherapy : CII, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- The effects of EPA and DHA enriched fish oil on nutritional and immunological markers of treatment naïve breast cancer patients: a randomized double-blind controlled trial.Nutrition journal · 2017Trial
- A Mathematical Model of Breast Tumor Progression Based on Immune Infiltration.Journal of personalized medicine · 2021Article
- Hampering Stromal Cells in the Tumor Microenvironment as a Therapeutic Strategy to Destem Cancer Stem Cells.Cancers · 2021Review
- Immunostimulatory Properties of Chemotherapy in Breast Cancer: From Immunogenic Modulation Mechanisms to Clinical Practice.Frontiers in immunology · 2021Review
- Role of regulatory T cells and CD8Oncology letters · 2018Article
- A novel potential effective strategy for enhancing the antitumor immune response in breast cancer patients using a viable cancer cell-dendritic cell-based vaccine.Oncology letters · 2018Article
- CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation.Journal for immunotherapy of cancer · 2018Article
- A panel containing PD-1, IL-2Rα, IL-10, and CA15-3 as a biomarker to discriminate breast cancer from benign breast disease.Cancer management and research · 2018Article
- Predictive value of peripheral regulatory T cells in non-small cell lung cancer patients undergoing radiotherapy.Oncotarget · 2017Article
- Frequency of CD4+CD25+Foxp3+ cells in peripheral blood in relation to urinary bladder cancer malignancy indicators before and after surgical removal.Oncotarget · 2016Article
- Antitumour actions of interferons: implications for cancer therapy.Nature reviews. Cancer · 2016Review
- Article
- Higher circulating levels of chemokine CCL22 in patients with breast cancer: evaluation of the influences of tumor stage and chemokine gene polymorphism.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Expansion of CD14(+)CD16(+) monocytes is related to acute leukemia.International journal of clinical and experimental medicine · 2015Article
- Bone specific immunity and its impact on metastasis.BoneKEy reports · 2015Review
- C/EBPβ expression is an independent predictor of overall survival in breast cancer patients by MHCII/CD4-dependent mechanism of metastasis formation.Oncogenesis · 2014Article
- Levels of lymphocyte subsets in peripheral blood prior treatment are associated with aggressive breast cancer phenotypes or subtypes.Medical oncology (Northwood, London, England) · 2014Article
- CD4+CD25(high), CD8+CD28- cells and thyroid autoantibodies in breast cancer patients.Central-European journal of immunology · 2014Article
- Loss of Dab2 expression in breast cancer cells impairs their ability to deplete TGF-β and induce Tregs development via TGF-β.PloS one · 2014Article
- Tumor-released survivin induces a type-2 t cell response and decreases cytotoxic T cell function, in vitro.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Expression levels of VEGF and Her-2, levels of T-regulatory (Treg) cells, levels of CD3+ cells, and ratios of Th (CD4+ T cells)/Tr (Treg) cells were compared between stage I, II, III, and IV breast cancer patients (n = 120) prior to chemotherapy and healthy women (n = 30). Cells from peripheral blood were counted by flow cytometry, Her-2 and VEGF expression was detected by pathological examination, and Her-2 was detected by FISH. Breast cancer patients had more Treg cells and a lower ratio of Th/Tr cells than the healthy women. Stage IV breast cancer patients had more Treg cells and a lower ratio of Th/Tr cells than stage I, II, or III breast cancer patients. Patients positive for VEGF had a lower ratio of Th/Tr cells compared with patients negative for VEGF, and those positive for both VEGF and Her-2 also had a lower ratio of Th/Tr cells compared with patients not positive for both VEGF and Her-2. The decreased Th/Tr cells ratio indicates impaired immune function, suggesting that the stage IV breast cancer and the Her-2/VEGF-positive breast cancer patients have lower immune function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.